IL204547A - Oracil derivative for the treatment of hepatitis c - Google Patents
Oracil derivative for the treatment of hepatitis cInfo
- Publication number
- IL204547A IL204547A IL204547A IL20454710A IL204547A IL 204547 A IL204547 A IL 204547A IL 204547 A IL204547 A IL 204547A IL 20454710 A IL20454710 A IL 20454710A IL 204547 A IL204547 A IL 204547A
- Authority
- IL
- Israel
- Prior art keywords
- treating hepatitis
- uracil derivative
- uracil
- derivative
- hepatitis
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US9679108P | 2008-09-13 | 2008-09-13 | |
| PCT/US2008/076576 WO2009039127A1 (en) | 2007-09-17 | 2008-09-17 | Uracil or thymine derivative for treating hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL204547A0 IL204547A0 (en) | 2010-11-30 |
| IL204547A true IL204547A (en) | 2016-04-21 |
Family
ID=39948002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL204547A IL204547A (en) | 2007-09-17 | 2010-03-16 | Oracil derivative for the treatment of hepatitis c |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (enExample) |
| EP (2) | EP2222646B1 (enExample) |
| JP (2) | JP5734654B2 (enExample) |
| KR (2) | KR101552474B1 (enExample) |
| CN (2) | CN102746239B (enExample) |
| AR (2) | AR070027A1 (enExample) |
| AU (1) | AU2008302448B2 (enExample) |
| BR (1) | BRPI0816994B8 (enExample) |
| CA (2) | CA2699981C (enExample) |
| CL (2) | CL2008002794A1 (enExample) |
| CO (1) | CO6260076A2 (enExample) |
| CR (2) | CR11316A (enExample) |
| DO (2) | DOP2010000084A (enExample) |
| ES (1) | ES2453591T3 (enExample) |
| GT (1) | GT201000061A (enExample) |
| IL (1) | IL204547A (enExample) |
| IN (1) | IN2012DN05113A (enExample) |
| MX (2) | MX2010002905A (enExample) |
| MY (1) | MY162760A (enExample) |
| NZ (3) | NZ584720A (enExample) |
| PA (1) | PA8796201A1 (enExample) |
| PE (2) | PE20130209A1 (enExample) |
| PH (1) | PH12013500365A1 (enExample) |
| RU (2) | RU2543620C2 (enExample) |
| SG (1) | SG183733A1 (enExample) |
| TW (2) | TWI534137B (enExample) |
| UA (1) | UA117800C2 (enExample) |
| UY (1) | UY31344A1 (enExample) |
| WO (1) | WO2009039127A1 (enExample) |
| ZA (2) | ZA201204223B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI534137B (zh) | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| PT2203431E (pt) | 2007-09-17 | 2011-10-12 | Abbott Lab | Pirimidinas anti-infecciosas e seus usos |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN102099351A (zh) * | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
| BRPI0916233A2 (pt) | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
| KR20110061640A (ko) | 2008-09-26 | 2011-06-09 | 에프. 호프만-라 로슈 아게 | Ｈｃｖ 치료용 피린 또는 피라진 유도체 |
| CN102361858B (zh) * | 2009-03-24 | 2014-07-23 | 艾伯维巴哈马有限公司 | 制备抗病毒化合物的方法 |
| CA2755023C (en) * | 2009-03-25 | 2016-12-13 | Abbott Laboratories | Antiviral compounds and uses thereof |
| EP2411007A4 (en) * | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| CA2758838A1 (en) | 2009-04-25 | 2010-10-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| SG176976A1 (en) * | 2009-06-24 | 2012-02-28 | Hoffmann La Roche | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| AU2010297290A1 (en) | 2009-09-21 | 2012-03-15 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| KR20120085918A (ko) * | 2009-11-21 | 2012-08-01 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| TW201144298A (en) * | 2009-12-14 | 2011-12-16 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| US9216952B2 (en) * | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| MX2012014235A (es) | 2010-07-07 | 2013-01-28 | Hoffmann La Roche | Compuestos hetericiclicos antiviricos. |
| EA028082B1 (ru) | 2010-07-16 | 2017-10-31 | ЭббВи Айэленд Анлимитед Компани | Способ получения сульфонамидного противовирусного соединения |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| WO2012009698A1 (en) | 2010-07-16 | 2012-01-19 | Abbott Laboratories | Phosphine ligands for catalytic reactions |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| MX2013001273A (es) | 2010-08-13 | 2013-04-10 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| EP2685964A1 (en) | 2011-03-18 | 2014-01-22 | AbbVie Inc. | Formulations of phenyl uracil compounds |
| EP2691118B1 (de) * | 2011-03-31 | 2019-05-01 | Schäfer, Konstanze | Perfluorierte verbindungen zum nicht-viralen transfer von nukleinsäuren |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| US9040516B2 (en) | 2011-08-01 | 2015-05-26 | Sumitomo Dainippon Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
| BR112014006314A2 (pt) | 2011-10-21 | 2017-04-11 | Abbvie Inc | métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon |
| PT107925A (pt) | 2011-10-21 | 2014-12-03 | Abbvie Inc | Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| PT2900637T (pt) | 2012-05-15 | 2017-11-15 | Novartis Ag | Derivados de amida de pirimidina, piridina e pirazina substituídos com tiazole ou imidazole e compostos relacionados como inibidores de abl1, abl2 e bcr-abl1 para tratamento do cancro, infecções virais específicas e disturbios do snc específicos |
| US9278981B2 (en) | 2012-05-15 | 2016-03-08 | Novartis Ag | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| AP3613A (en) | 2012-05-15 | 2016-02-29 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1 |
| CN104302634B (zh) | 2012-05-15 | 2017-02-08 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
| MX2014015942A (es) | 2012-06-27 | 2015-07-17 | Abbvie Inc | Tratamiento de combinacion con abt-450 y ritonavir y e. g. abt-072 y/o abt-333 para utilizarse en el tratamiento del vhc. |
| CN104884440A (zh) * | 2012-08-21 | 2015-09-02 | 艾伯维公司 | 用于制备抗病毒化合物的方法 |
| WO2014063101A1 (en) | 2012-10-18 | 2014-04-24 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| AU2014284455A1 (en) | 2013-07-02 | 2016-01-21 | Abbvie Inc. | Methods for treating HCV |
| EP3019481B1 (de) | 2013-07-08 | 2019-03-06 | Bayer CropScience Aktiengesellschaft | Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US20150209403A1 (en) | 2014-01-28 | 2015-07-30 | Abbvie Inc. | Dose Adjustment |
| CA2938311C (en) | 2014-02-03 | 2023-03-07 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| US10517870B2 (en) * | 2015-07-30 | 2019-12-31 | Bristol-Myers Squibb Company | Aryl substituted bicycle heteroaryl compounds |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| BR112018010018A2 (pt) | 2015-11-20 | 2018-11-21 | Vitae Pharmaceuticals Inc | moduladores de ror-gama |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| CN111936498B (zh) | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| JP7785663B2 (ja) * | 2019-09-16 | 2025-12-15 | ノバルティス アーゲー | 二機能性分解誘導薬及びそれらの使用方法 |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5162326A (en) | 1990-02-15 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (enExample) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| SI1237878T1 (sl) | 1999-12-06 | 2007-08-31 | Hoffmann La Roche | 4-pirimidinil-n-acil-l-fenilanin |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| IL141034A0 (en) * | 2000-02-04 | 2002-02-10 | Sumitomo Chemical Co | Uracil compounds and use thereof |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TWI394747B (zh) * | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| PT2203431E (pt) | 2007-09-17 | 2011-10-12 | Abbott Lab | Pirimidinas anti-infecciosas e seus usos |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| TWI534137B (zh) * | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| BRPI0916233A2 (pt) | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
-
2008
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL204547A (en) | Oracil derivative for the treatment of hepatitis c | |
| IL257418A (en) | Methods for treating addiction | |
| ZA200906129B (en) | Compounds for the treatment of hepatitis c | |
| LT2754660T (lt) | Piridazinono dariniai | |
| ZA201101739B (en) | Compounds for the treatment of hepatitis c | |
| EP2343066A4 (en) | THERAPEUTIC AGENT FOR HEPATITIS C | |
| IL204736A0 (en) | Heterocyclic antiviral compounds | |
| ZA200909054B (en) | Pyridazinone Derivatives | |
| IL205611A0 (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| ZA201009183B (en) | Heterocyclic antiviral compounds | |
| IL200661A0 (en) | Heterocyclic antiviral compounds | |
| IL196876A0 (en) | 2-(heterocyclylbenzyl)pyridazinone derivatives | |
| ZA201105440B (en) | Pyridazinone derivatives | |
| IL212636A0 (en) | Pyridazinone derivatives | |
| EP2123631A4 (en) | PROCESS FOR PRODUCTION OF -ALCOXYPROPIONAMIDE | |
| ZA201008330B (en) | Pyridazinone derivatives | |
| ZA201003815B (en) | Heterocyclic antiviral compounds | |
| PL2209784T3 (pl) | Związki do leczenia zapalenia wątroby typu C | |
| ZA201000923B (en) | Compounds for the treatment of hepatitis c | |
| ZA201104362B (en) | Heterocyclic antiviral compounds | |
| EP2163554A4 (en) | PYRIMIDODIAZEPINONE DERIVATIVE | |
| EP1986651A4 (en) | USE OF A PYRIMIDINE DERIVATIVE FOR THE PREVENTION OR TREATMENT OF HEPATITIS C | |
| IL236462A0 (en) | triazine derivative compounds | |
| ZA200802123B (en) | Benzodiazepine derivatives for treating hepatitis C infection | |
| ZA201000867B (en) | Methods for treating dependence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXTF | Application for patent extension filed |
Filing date: 20150528 |
|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| PEL | Intention of commissioner to extend period of protection |
Free format text: PRODUCT NAME: DASABUVIR Extension date: 20281219 |
|
| KB | Patent renewed |